LRMR — Larimar Therapeutics Share News
0.000.00%
Last trade - 00:00- $313.73m
- $157.46m
Larimar Therapeutics Inc reports results for the quarter ended in December - Earnings Summary
Brief: Larimar Therapeutics Q4 Net Income USD -12.993 Million
Brief: Larimar Therapeutics Announces Dosing Of First Patient In Long-Term Open Label Extension Study For Nomlabofusp
Larimar Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-CME Group, Robinhood Markets, Citigroup
Larimar Therapeutics extends rally after $150 mln stock offering
Brief: Larimar Therapeutics Announces Pricing Of Underwritten Public Offering Of Common Stock
Brief: Larimar Therapeutics- Gave Notice To Terminate Sales Agreement With Guggenheim Securities
Brief: Larimar Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg Cohorts of Nomlabofusp
Brief: Larimar Therapeutics Says Increased Size Of Board From Five To Six Members
Brief: Larimar Therapeutics Appoints Jeffery Sherman To Its Board Of Directors
Larimar Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Larimar Therapeutics Q2 Net Income USD -8.366 Million
Larimar Therapeutics Inc expected to post a loss of 19 cents a share - Earnings Preview
Larimar Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Larimar Therapeutics Reports Preliminary Top-Line Data From Phase 2 Trial’S 25 MG Cohort
Larimar Therapeutics Inc expected to post a loss of 25 cents a share - Earnings Preview
Brief: Larimar Therapeutics Reports Fourth Quarter And Full Year 2022 Operating And Financial Results
Brief: Larimar Therapeutics Appoints Dr. Gopi Shankar As Chief Development Officer